Top Markets
Coin of the day
Greenyn Biotechnology Co., Ltd Greenyn Biotechnology Co., Ltd

Greenyn Biotechnology Co., Ltd

6846
Rank in Stocks #25419
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary... Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ingredients. These feature notable components such as Insumate, derived from bitter melon extract; Antromax, which utilizes antrodia cinnamomea; and the Zymologist 101 Phyto fermented drink. Beyond individual ingredients, Greenyn provides an extensive selection of functional product series catering to a diverse array of health and wellness needs. These encompass solutions for youth and beauty, digestive and brain health, overall body regulation, throat care, hair care, vision support, and various lifestyle enhancement formulas. Additional ranges include joint health, general nutritional and energy supplementation, immune modulation, low-burden options, sleep assistance, body contouring, circulatory support, specific formulas for men's vitality and women's intimate health, and dedicated products for mature women. Moreover, the company extends its expertise through various services, including custom product development, Original Design Manufacturing (ODM), dosage form optimization, and application support. Established in 2012, the firm's operations are headquartered in Taichung, Taiwan.
Share Price
$1.84
Market Cap
$49.75M
Change (1 day)
0.87%
Change (1 year)
-24.88%
Country
TW
Trade Greenyn Biotechnology Co., Ltd (6846)

Category

Revenue for Greenyn Biotechnology Co., Ltd (6846)
Revenue in Aug 2026 TTM: 0
According to Greenyn Biotechnology Co., Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Greenyn Biotechnology Co., Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US